BOLD THERAPEUTICS
Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic. Its product BOLD-100, a ruthenium-based small molecule therapeutic, improves the activity of a wide range of other anti-cancer therapies by disabling a critical and previously untargeted cancer resistance, survival, and proliferation pathway. Bold Therapeutics is focusing its clinical development efforts on some of the most challenging cancer indications where existing therapies are largely ineffective, resulting in a significant unmet medical need.
BOLD THERAPEUTICS
Industry:
Biotechnology Health Care Therapeutics
Founded:
2018-01-01
Address:
Vancouver, British Columbia, Canada
Country:
Canada
Website Url:
http://www.bold-therapeutics.com
Total Employee:
11+
Status:
Active
Contact:
+1 (604) 262-9899
Email Addresses:
[email protected]
Total Funding:
1.09 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Apple Mobile Web Clips Icon Font Awesome IPv6 Google Apps For Business Google Maps PHP
Similar Organizations
Cedilla Therapeutics
Cedilla Therapeutics is a biotechnology company that develops targeted small molecules for the treatment of cancer and other diseases.
Context Therapeutics
Context Therapeutics is a clinical-stage biopharmaceutical company.
Edgewise Therapeutics
Edgewise Therapeutics is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization.
Remix Therapeutics
Remix Therapeutics is a biotechnology company.
Current Employees Featured
Investors List
National Research Council of Canada Industrial Research Assistance Program
National Research Council of Canada Industrial Research Assistance Program investment in Grant - Bold Therapeutics
National Research Council of Canada Industrial Research Assistance Program
National Research Council of Canada Industrial Research Assistance Program investment in Venture Round - Bold Therapeutics
Official Site Inspections
http://www.bold-therapeutics.com
- Host name: server-52-85-78-51.ord51.r.cloudfront.net
- IP address: 52.85.78.51
- Location: Seattle United States
- Latitude: 47.6348
- Longitude: -122.3451
- Metro Code: 819
- Timezone: America/Los_Angeles
- Postal: 98109
More informations about "Bold Therapeutics"
Bold Therapeutics | Company
Bold Therapeutics is a clinical-stage biopharma company based in Vancouver, British Columbia founded in 2018 to develop and commercialize BOLD-100, a first-in-class metallotherapeutic …See details»
Bold Therapeutics - Crunchbase Company Profile
Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic. Its product BOLD-100, a …See details»
Bold Therapeutics - N2 Canada
Bold Therapeutics, based in Vancouver, British Columbia, is a clinical-stage oncology company focused on developing BOLD-100, a ruthenium-based …See details»
Bold Therapeutics Inc Company Profile - Dun & Bradstreet
Find company research, competitor information, contact details & financial data for Bold Therapeutics Inc of Vancouver, BC. Get the latest business insights from Dun & Bradstreet.See details»
Bold Therapeutics - Funding, Financials, Valuation & Investors
Bold Therapeutics is a clinical-stage biotech company that develops and commercializes an anti-resistance therapeutic. New. Resources. Advanced Search. ... How much funding has this …See details»
Bold Therapeutics, Inc. - Drug pipelines, Patents, …
Explore Bold Therapeutics, Inc. with its drug pipeline, therapeutic area, technology platform, 1 clinical trial, 19 news, and 5 literature, Disease Domain:Neoplasms, Endocrinology and Metabolic Disease, Technology …See details»
Bold Therapeutics - Overview, News & Similar companies
Jan 21, 2024 Who is Bold Therapeutics. Bold Therapeutics is headquartered in Vancouver, British Columbia , Canada. BOLD-100 is currently being investigated in a Phase 1b /2 study in …See details»
Bold Therapeutics - VentureRadar
" Bold Therapeutics is a clinical-stage pharmaceutical company that was founded in 2018 by a team of industry veterans to develop and commercialize novel therapeutics. The company’s …See details»
Bold Therapeutics Inc. - Life Sciences British Columbia
Jun 3, 2021 Bold Therapeutics is a clinical-stage biopharmaceutical company based in Vancouver, British Columbia, founded in 2018 to develop and commercialize BOLD-100, a first …See details»
Bold Therapeutics | Welcome
A Phase 2 clinical trial of BOLD-100 in combination with FOLFOX for the treatment of advanced gastrointestinal (bile duct, colon, gastric, and pancreatic) cancers (NCT04421820) is ongoing. …See details»
Bold Therapeutics - Biotech Careers
Bold Therapeutics is a clinical-stage biopharma company working to develop and commercialize BOLD-100, a first-in-class small molecule therapeutic with applications in both oncology …See details»
Bold Therapeutics Company Profile - Office Locations ... - Craft
Bold Therapeutics is a biotechnology company developing cancer therapy for the treatment of gastric, pancreatic, colorectal, and other cancers. It offers BOLD-100, a ruthenium-based …See details»
Bold Therapeutics - PitchBook
Bold Therapeutics General Information Description. Developer of novel metallo therapeutics (metal-based small molecules designed for the treatment of cancer. The company's lead …See details»
News - Bold Therapeutics
Bold Therapeutics announced positive Phase 2 result for BOLD-100 in the treatment of advanced metastatic biliary tract cancer and gastric cancer at ASCO 2024. 04-04-2024 BOLD-100 and …See details»
BOLD-200 - Drug Targets, Indications, Patents - Synapse
BOLD-200, Initially developed by Bold Therapeutics, Inc., Now, its global highest R&D status is Preclinical, Active Org.: Bold Therapeutics, Inc.. ... Active Organization. Bold Therapeutics, …See details»
Bold Therapeutics - Products, Competitors, Financials, Employees ...
Bold Therapeutics is a clinical-stage biopharmaceutical company focused on the development of metallotherapeutics for advanced cancer treatment. The company utilizes metal-based …See details»
Bold Therapeutics - Updates, News, Events, Signals & Triggers
Bold Therapeutics announced positive Phase 2 safety and efficacy results for BOLD-100 in advanced metastatic biliary tract and gastric cancers at ASCO 2024. Additionally, the …See details»
Bold Therapeutics Successfully Initiates Clinical Trial of First-in ...
Oct 9, 2020 “Bold Therapeutics is working with an experienced team of investigators across Canada – and, later, in the United States and South Korea – for this groundbreaking clinical …See details»
Technology - Bold Therapeutics
Bold Therapeutics' BOLD-100 is a first-in-class ruthenium-based small molecule therapeutic with a multimodal mechanism-of-action and broad therapeutic potential, high potency, and low …See details»
Effects of KCNQ potassium channel modulation on ventral
2 days ago Although BOLD activity in VTA does not measure VTA-DA neuron excitability, studies using pharmacological-MRI and fast-scan cyclic voltammetry in humans and non …See details»